ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.2099C>A (p.Ala700Glu)

dbSNP: rs876658251
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000215093 SCV000273252 pathogenic Hereditary cancer-predisposing syndrome 2024-04-24 criteria provided, single submitter clinical testing The p.A700E pathogenic mutation (also known as c.2099C>A), located in coding exon 13 of the MSH2 gene, results from a C to A substitution at nucleotide position 2099. The alanine at codon 700 is replaced by glutamic acid, an amino acid with dissimilar properties. This variant has been identified in a proband whose Lynch syndrome-associated tumor demonstrated high microsatellite instability and loss of both MSH2/MSH6 expression by immunohistochemistry (Ambry internal data). In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was determined to be functionally deleterious (Jia X et al. Am J Hum Genet, 2021 01;108:163-175). This variant was also identified in a genetic screen that measured tolerance to 6-TG in a cell survival assay indicating mismatch repair deficiency was present (Drost M et al. Proc Natl Acad Sci U S A, 2013 Jun;110:9403-8). The yeast equivalent of this variant demonstrated an increased mutation rate compared to wild type in a multiplexed functional assay performed using Saccharomyces cerevisiae (Ollodart AR et al. Genetics, 2021 Jun;218). Based on internal structural analysis, p.A700E is more disruptive to the MSH2 MutS domain V than several nearby pathogenic variants (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation.
Myriad Genetics, Inc. RCV003454614 SCV004186631 likely pathogenic Lynch syndrome 1 2023-08-07 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 33357406]. This variant is expected to disrupt protein structure [Myriad internal data].

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.